High-grade neuroendocrine carcinoma (NEC) can be difficult to diagnose, particularly when conventional neuroendocrine (NE) markers are weakly expressed or absent. This challenge is particularly pronounced in NE-low tumors with lineage-defining transcription factor profiles (e.g., POU2F3 and/or YAP1), which may exhibit squamoid (basal-like) morphology and reduced or absent expression of synaptophysin (Syn), chromogranin A (CgA), and CD56, thereby phenotypically overlapping with non-small cell lung cancer (NSCLC) and increasing the risk of misclassification.
In this case, needle biopsies from the lung and liver both showed a poorly differentiated carcinoma with squamoid morphology and squamoid/basal-like immunohistochemical features. Syn, CgA, and CD56 were negative in both specimens, leading to an initial diagnosis of poorly differentiated squamous cell carcinoma.
However, the subsequent clinical course revealed discordant clinicobiologic features, including rapid progression of the liver metastases, markedly elevated NSE levels, and a high Ki-67 labeling index (60–80%). These discrepancies prompted further molecular evaluation, and 90-gene expression profiling (90-GEP) supported a neuroendocrine lineage assignment.
Frontiers in Immunology published a clinical update in Infectious Disease on 08 May 2026.
The item focuses on Case Report: Neuroendocrine-marker–negative high-grade neuroendocrine carcinoma mimicking squamous cell carcinoma: an underrecognized diagnostic pitfall.
Review the original article for the full source wording and details.